This is a mechanism module, not a specific disease. Disorder entries reference individual nodes via conforms_to (e.g. "sleep_disordered_breathing_intermittent_hypoxia#Chronic Intermittent Hypoxia and Reoxygenation", the key conformance target and rate-limiting step).
ARM SELECTION. Enter at #Sleep-Related Loss of Upper Airway Dilator Compensation in a Collapsible Pharynx for obstructive disease, and at #Ventilatory Control Instability or Chemoreflex Failure for central disease. The arms are not alternatives to be picked by convenience: an obstructive entry has flow limitation against continued respiratory effort, a central entry has absent effort. They frequently coexist in one patient - a high loop gain is present in about a third of patients with anatomically obstructive apnoea and is what turns a marginal airway into a cycling one - so a disorder entry may honestly conform to both, but should say which lesion it is evidencing at each node.
THE INTERMITTENT-VERSUS-SUSTAINED BOUNDARY, which conformers must not blur. The central node is specifically CYCLICAL desaturation followed by reoxygenation; the reoxygenation half is not incidental, it is the source of the superoxide burst that drives the downstream vascular arm, which is why intermittent hypoxia and sustained hypoxia of the same average severity have different consequences. A disorder whose gas-exchange lesion is sustained nocturnal hypoventilation with hypercapnia rather than cyclical desaturation - congenital central hypoventilation syndrome is the clearest case, and neuromuscular and obesity hypoventilation are others - conforms at #Ventilatory Control Instability or Chemoreflex Failure and may conform at the systemic sequelae, but must NOT conform at #Chronic Intermittent Hypoxia and Reoxygenation. Recording that distinction is the point of the module for those entries.
HETEROGENEITY IS CURATED, NOT SMOOTHED. Obstructive sleep apnoea is not one mechanism with one severity axis. Endotyping shows four largely independent traits - pharyngeal collapsibility, genioglossus responsiveness, arousal threshold, and loop gain - and non-anatomic traits contribute importantly in the majority of patients. A conforming disorder entry that curates only airway anatomy has curated one of four, and the apnoea-hypopnoea index it is typically graded by is a count of events rather than a measure of any of them.
DEVICE-TARGET PATTERN. Continuous positive airway pressure INHIBITS #Recurrent Apnoea-Hypopnoea with Arousal from Sleep by pneumatically splinting the airway. It is the module's mechanistic proof that the apnoeic events, not a shared antecedent such as obesity, cause the downstream chain - but note the honest caveat curators must preserve: greater physiological efficacy does not translate into proportionally greater clinical effectiveness, because adherence is the binding constraint, and a less efficacious device used for more of the night can deliver equivalent health outcomes.
SCOPE BOUNDARIES. Distinct from orexin_arousal_instability (sleepiness from an unstable state switch with normal breathing) and circadian_phase_misalignment (sleep correctly structured but mistimed). The downstream vascular arm feeds atherogenesis and the systemic hypertension pathway rather than re-deriving them.
Not an Xogenesis module - a physiological control loop fails, nothing pathological is formed.
Is the apnoea-hypopnoea index an adequate measure of the exposure this module makes rate-limiting?
KNOWLEDGE GAP
gap_ahi_as_severity_metric
Attached to:
Chronic Intermittent Hypoxia and Reoxygenation
Recurrent Apnoea-Hypopnoea with Arousal from Sleep
Every diagnostic threshold, severity band, and trial eligibility criterion in this field uses the apnoea-hypopnoea index, a count of events per hour. But the module's causal quantity is the cyclical hypoxic exposure, and two patients with identical event counts can differ several-fold in desaturation depth, hypoxic burden, and arousal intensity. That mismatch is a plausible contributor to the repeated failure of CPAP trials powered on index-based severity to show cardiovascular benefit, and it means a conforming disorder entry curating "severe OSA" by index has not necessarily curated severe exposure at the central node.
Proposed experiments:
Hypoxic burden versus event index as predictors of cardiovascular outcome
Ventilatory Control Instability or Chemoreflex Failure
trigger
Second entry arm, mechanistically distinct from the first, and itself covering two opposite control failures. In the UNSTABLE case, chemoreflex loop gain is high: a small ventilatory perturbation provokes an overcorrection, driving arterial carbon dioxide below the apnoeic threshold, which stops respiratory effort altogether until carbon dioxide reaccumulates, and the loop oscillates. This is the mechanism of idiopathic central sleep apnoea and of the Cheyne-Stokes pattern in heart failure, and - because loop gain is a continuously distributed trait - it also destabilises airways that anatomy alone would have left marginal. In the HYPORESPONSIVE case, the chemoreflex fails to respond at all: central chemoreception to carbon dioxide is absent or blunted, so no corrective ventilatory response is generated and the result is sustained hypoventilation rather than oscillation. Conforming disorder nodes must state which failure they evidence, because the two predict opposite responses to supplemental oxygen and to respiratory stimulants.
Downstream
-
Recurrent Apnoea-Hypopnoea with Arousal from Sleep
Oscillation of the chemoreflex loop drives arterial carbon dioxide below the apnoeic threshold, producing central apnoeas that terminate in arousal as carbon dioxide reaccumulates. This edge applies to the unstable (high-loop-gain) failure; the hyporesponsive failure produces sustained hypoventilation and does not traverse it.
Recurrent Apnoea-Hypopnoea with Arousal from Sleep
amplifier
Both arms converge here. Airflow is repeatedly abolished or reduced, gas exchange deteriorates until chemical and mechanical stimuli reach the arousal threshold, and a cortical arousal restores airway patency or ventilatory drive - after which sleep resumes and the cycle repeats, often hundreds of times a night. The arousal is simultaneously the corrective mechanism and a source of injury: it fragments sleep and delivers a sympathetic surge at each event. The arousal threshold is therefore genuinely double-edged, and a low threshold is a distinct endotype rather than a marker of severity - patients who arouse too easily terminate events before dilator recruitment can stabilise the airway, which is why sedating such patients can paradoxically reduce their event count.
Downstream
-
Chronic Intermittent Hypoxia and Reoxygenation
Each cycle of obstruction and relief produces a fall and then a rapid restoration of arterial oxygen saturation, repeated through the night.
Chronic Intermittent Hypoxia and Reoxygenation
central effector
The rate-limiting, disorder-agnostic node and the key conformance target. The exposure that drives systemic disease is not hypoxia but the cycle: repeated desaturation followed by rapid reoxygenation, delivered hundreds of times nightly for years. The reoxygenation phase is mechanistically essential, because it is the ischaemia-reperfusion-like burst of reactive oxygen species, rather than the oxygen debt, that sensitises the carotid body and initiates the vascular arm. This is why an equivalent time-averaged oxygen saturation delivered continuously does not reproduce the phenotype, and why disorders whose lesion is sustained nocturnal hypoventilation must not conform here.
Downstream
-
Sympathetic Overactivation, Oxidative Stress and Vascular Inflammation
Cyclical hypoxia and reoxygenation sensitise the peripheral chemoreflex and generate reactive oxygen species in the vascular wall.
Sympathetic Overactivation, Oxidative Stress and Vascular Inflammation
effector
Chemoreceptor sensitisation converts a nocturnal, intermittent stimulus into a tonic, daytime elevation of sympathetic vasoconstrictor outflow that persists long after the patient has woken - which is the step that makes a sleep disorder into a cardiovascular one. In parallel, superoxide overproduction and inflammatory activation act directly on resistance vessels. The two mechanisms are additive rather than alternative, and both are needed to explain the hypertension.
Downstream
-
Cardiovascular, Metabolic and Neurocognitive Sequelae
Sustained sympathetic and oxidative-inflammatory activation, together with sleep fragmentation, produce the systemic consequences.